APS.TO - Aptose Biosciences Inc.

Toronto - Toronto Delayed Price. Currency in CAD
7.65
-0.03 (-0.39%)
As of 11:39AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close7.68
Open7.67
Bid7.63 x 0
Ask7.67 x 0
Day's Range7.56 - 7.75
52 Week Range2.08 - 8.21
Volume12,318
Avg. Volume71,045
Market Cap582.209M
Beta (5Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-0.55
Earnings DateNov 04, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
  • GlobeNewswire

    Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference

    SAN DIEGO and TORONTO, Jan. 07, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • GlobeNewswire

    Aptose Announces Closing of Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the “Offering”) at the public offering price of US$4.00 per share. The number of shares sold includes the full exercise by the underwriters of their option to purchase additional common shares in the Offering. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are approximately US$74.2 million.

  • Hedge Funds Have Never Been This Bullish On Aptose Biosciences Inc (APTO)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Aptose Biosciences Inc (APTO)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    Aptose Announces Pricing of Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the “Offering”) at a price of US$4.00 per share. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are expected to be approximately US$64.5 million. The underwriters have been granted a 30-day option to purchase up to an additional 2,418,750 common shares in the Offering, under the same terms and conditions.

  • GlobeNewswire

    Aptose Announces Proposed Public Offering of Common Shares

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the Underwriters a 30-day option to purchase up to an additional 15% of the common shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire

    Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

    SAN DIEGO and TORONTO, Dec. 09, 2019 -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics.

  • GlobeNewswire

    Aptose Presents Highlights From Corporate Event At ASH

    SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today.

  • GlobeNewswire

    Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

    Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Rafael Bejar, M.D., Ph.D., to the position of Senior Vice President, Chief Medical Officer, effective January 1, 2020. In his role as a member of the executive leadership team, Dr. Bejar will oversee global clinical development and regulatory initiatives for Aptose, as well as other research activities. “Rafael is a physician-scientist whose depth of experience both in the research setting and in treating patients with hematologic malignancies brings a unique and important perspective as we accelerate the clinical development of our hematologic product candidates,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

  • GlobeNewswire

    Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

    SAN DIEGO and TORONTO, Dec. 02, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • Thomson Reuters StreetEvents

    Edited Transcript of APS.TO earnings conference call or presentation 5-Nov-19 10:00pm GMT

    Q3 2019 Aptose Biosciences Inc Earnings Call

  • Is Aptose Biosciences (TSE:APS) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Aptose Biosciences (TSE:APS) In A Good Position To Deliver On Growth Plans?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Aptose to Present at BIO-Europe Conference

    SAN DIEGO and TORONTO, Nov. 07, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.

  • GlobeNewswire

    Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

    – Company to Hold Event During ASH –  – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 -- Aptose Biosciences Inc. (“Aptose”).

  • GlobeNewswire

    Aptose Reports Results for the Third Quarter Ended September 30, 2019

    CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical.

  • GlobeNewswire

    Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019

    SAN DIEGO and TORONTO, Oct. 22, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target.

  • GlobeNewswire

    Aptose to Participate at 5th International Conference on Acute Myeloid Leukemia of the European School of Haematology (ESH)

    SAN DIEGO and TORONTO, Oct. 10, 2019 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

  • GlobeNewswire

    Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies

    SAN DIEGO and TORONTO, Sept. 16, 2019 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.

  • How Much Are Aptose Biosciences Inc. (TSE:APS) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Aptose Biosciences Inc. (TSE:APS) Insiders Spending On Buying Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Thomson Reuters StreetEvents

    Edited Transcript of APS.TO earnings conference call or presentation 6-Aug-19 9:00pm GMT

    Q2 2019 Aptose Biosciences Inc Earnings Call

  • GlobeNewswire

    Aptose Reports Results for the Second Quarter Ended June 30, 2019

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced financial results for the three months ended June 30, 2019 and reported on corporate developments. The net loss for the quarter ended June 30, 2019 was $6.2 million ($0.13 per share) compared with $10.3 million ($0.30 per share) for the quarter ended June 30, 2018. Total cash and cash equivalents and investments as of June 30, 2019 were $35.4 million.

  • GlobeNewswire

    Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference

    SAN DIEGO and TORONTO, July 30, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the.

  • GlobeNewswire

    Aptose To Release Second Quarter Ended June 30, 2019 Financial Results and Hold Conference Call on August 6, 2019

    SAN DIEGO and TORONTO, July 23, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target.

  • GlobeNewswire

    Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

    SAN DIEGO and TORONTO, July 16, 2019 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that dosing of CG-806, the company’s highly potent, first-in-class pan-FLT3/pan-BTK inhibitor, has commenced its Phase 1a/b dose-escalation study in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or non-Hodgkin lymphomas (NHL) who have failed or are intolerant to standard therapies. In parallel, the company has successfully completed the first two dose levels of the Phase 1b clinical trial of MYC inhibitor APTO-253, and is now dosing the third dose cohort. Initial data from the first two cohorts demonstrate MYC inhibition in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

  • Thomson Reuters StreetEvents

    Edited Transcript of APS.TO earnings conference call or presentation 7-May-19 9:00pm GMT

    Q1 2019 Aptose Biosciences Inc Earnings Call

  • GlobeNewswire

    Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association

    Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new preclinical data for CG-806, its oral, first-in-class pan-FLT3/pan-BTK inhibitor, is being presented in a poster presentation today at the 24th Congress of the European Hematology Association in Amsterdam, the Netherlands. In the mice treated with 100 mg/kg, 5 of 11 (45%) were cured through day 120, and in the 300 mg/kg group, 10 of 11 (91%) of the mice were cured. Retreating the “uncured’ mice in these two dose groups for an additional 28 days beginning on day 88 led to rapid and robust antitumor response resulting in “cures” in all retreated mice through day 120.